Windsong Radiology introduces prostate cancer-focused radiopharmaceutical therapy

A new FDA-approved radiopharmaceutical, Xofigo, is now being offered at Windsong Radiology in New York for therapy used to treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC is resistant to other medical and surgical treatments that aim to lower testosterone levels in patients whose disease has spread to the bones.

According to Bayer HealthCare, who owns Xofigo, the treatment helps to extend life by more than 30 percent. While the injection goes to the bone, it does limited damage to nearby healthy cells. Patients who are eligible to receive the monthly administration are ones who have acceptable white blood cell and platelet counts and metastatic bone disease.

The American Cancer Society notes that prostate cancer is the most common type of cancer found in men, other than skin cancer. When prostate cancer spreads to other parts of the body, many times it will go to the bones, resulting in fast tumor growth. Patients who have received Xofigo, reported that not only do they live longer, but there is a delay in their first bone-related symptom or event.